Zelig Eshhar
#162,216
Most Influential Person Now
Zelig Eshhar's AcademicInfluence.com Rankings
Zelig Eshharbiology Degrees
Biology
#12921
World Rank
#16428
Historical Rank
Immunology
#873
World Rank
#896
Historical Rank
Biochemistry
#2231
World Rank
#2377
Historical Rank
Download Badge
Chemistry Biology
Zelig Eshhar's Degrees
- PhD Immunology Weizmann Institute of Science
Why Is Zelig Eshhar Influential?
(Suggest an Edit or Addition)Zelig Eshhar's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. (1993) (1265)
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. (1989) (1177)
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer (2006) (1088)
- In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. (1995) (278)
- A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity1 (2009) (275)
- Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain (1993) (247)
- Detection of a cytokeratin determinant common to diverse epithelial cells by a broadly cross‐reacting monoclonal antibody. (1982) (209)
- Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. (1993) (186)
- Photodynamic therapy with Pd‐bacteriopheophorbide (TOOKAD): Successful in vivo treatment of human prostatic small cell carcinoma xenografts (2003) (185)
- Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR (2000) (183)
- Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. (2014) (167)
- Lymphoid Cell Surface Interaction Structures Detected Using Cytolysis‐Inhibiting Monoclonal Antibodies (1982) (161)
- Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. (1981) (158)
- Generation of hybridomas secreting murine reaginic antibodies of anti-DNP specificity. (1980) (154)
- Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. (1989) (149)
- Functional expression of chimeric receptor genes in human T cells. (2001) (148)
- Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. (2008) (132)
- Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. (2009) (127)
- Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. (2002) (127)
- Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE (1984) (127)
- Variability and repertoire size of T-cell receptor Vα gene segments (1985) (124)
- Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. (2006) (122)
- Tumor-specific T-bodies: towards clinical application (1997) (116)
- Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. (2016) (116)
- Suppression of Human Prostate Tumor Growth in Mice by a Cytolytic d-, l-Amino Acid Peptide (2004) (112)
- Ferritin, a Hodgkin's disease associated antigen. (1974) (111)
- Reorganization of arrays of prekeratin filaments during mitosis. Immunofluorescence microscopy with multiclonal and monoclonal prekeratin antibodies. (1981) (106)
- Functional Comparison of Engineered T Cells Carrying a Native TCR versus TCR-like Antibody–Based Chimeric Antigen Receptors Indicates Affinity/Avidity Thresholds (2014) (105)
- The T-body approach: redirecting T cells with antibody specificity. (2008) (103)
- catELISA: a facile general route to catalytic antibodies. (1993) (100)
- Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity* (2005) (99)
- Engraftment and development of human T and B cells in mice after bone marrow transplantation. (1991) (98)
- Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity? (1995) (93)
- Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. (2004) (93)
- Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. (2003) (88)
- Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. (2012) (80)
- Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. (2005) (77)
- Metastatic properties conferred on nonmetastatic tumors by hybridization of spleen B-lymphocytes with plasmacytoma cells. (1981) (73)
- Endowing T cells with antibody specificity using chimeric T cell receptors (1992) (70)
- Cytotoxic T lymphocyte hybridomas that mediate specific tumor-cell lysis in vitro. (1981) (69)
- Structural Convergence in the Active Sites of a Family of Catalytic Antibodies (1997) (69)
- Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. (1998) (69)
- Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: structural similarities in esterase-like catalytic antibodies. (1995) (68)
- Development of adoptive cell therapy for cancer: a clinical perspective. (2010) (67)
- Growth inhibition of prostate cancer xenografts by halofuginone * † (2002) (66)
- T-cell hybridoma bearing heavy chain variable region determinants producing (T,G)-A--L-specific helper factor (1980) (66)
- Unusual Alternative Splicing within the Human Kallikrein Genes KLK2 and KLK3 Gives Rise to Novel Prostate-specific Proteins* (2002) (64)
- The T-body approach: potential for cancer immunotherapy (2004) (63)
- Simple method for selecting catalytic monoclonal antibodies that exhibit turnover and specificity. (1990) (63)
- Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. (1998) (62)
- Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization. (1979) (62)
- Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein. (1985) (61)
- Monoclonal antibodies against defined determinants of acetylcholine receptor (1979) (60)
- Monoclonal Antibody Strategy and Techniques (1985) (58)
- WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. (2000) (57)
- Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. (1998) (56)
- Use of monoclonal antibodies to pregnanediol-3α-glucuronide for the development of a solid phase chemiluminescence immunoassay (1981) (56)
- Calpain (Ca(2+)-dependent thiol protease) in erythrocytes of young and old individuals. (1994) (56)
- Measurement of plasma estradiol-17 beta by solid-phase chemiluminescence immunoassay. (1982) (54)
- Recognition of human colon cancer by T cells transduced with a chimeric receptor gene (2000) (52)
- Crystal structure of a catalytic antibody Fab with esterase-like activity. (1994) (51)
- Protective monoclonal antibody against Schistosoma mansoni: antigen isolation, characterization, and suitability for active immunization. (1985) (51)
- Monoclonal antibodies to human interferon‐gamma: production, affinity purification and radioimmunoassay. (1983) (51)
- X-ray structures of a hydrolytic antibody and of complexes elucidate catalytic pathway from substrate binding and transition state stabilization through water attack and product release. (1997) (50)
- Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. (2004) (50)
- Monoclonal immunoglobulin G augments hydrolysis of an ester of the homologous hapten (1980) (49)
- Monoclonal antibodies to human alpha-interferon and their use for affinity chromatography. (1982) (48)
- Mapping of the high affinity Fc epsilon receptor binding site to the third constant region domain of IgE. (1991) (48)
- Fine specificity of the IgE interaction with the low and high affinity Fc receptor. (1993) (45)
- Transport of 3-o-Methylglucose Into and Out of Storage Cells of Daucus carota. (1968) (43)
- The emergence of T-bodies/CAR T cells. (2014) (42)
- Quantitative detection of protein arrays. (2003) (42)
- In vitro and in vivo induction of effector T cells mediating DTH responses to a protein and a synthetic polypeptide antigen. (1979) (38)
- Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic. (2010) (38)
- Conformational changes affect binding and catalysis by ester-hydrolysing antibodies. (1999) (37)
- Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. (2020) (37)
- Expression characteristics of two potential T cell mediator genes. (1989) (36)
- Towards antibody-mediated metallo-porphyrin chemistry (1990) (35)
- Differences in the biochemical properties of esterolytic antibodies correlate with structural diversity. (1994) (34)
- Mapping of murine IgE epitopes involved in IgE‐Fcε receptor interactions (1989) (33)
- Monoclonal antibodies associated with sodium channel block nerve impulse and stain nodes of Ranvier (1984) (33)
- Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. (2014) (33)
- Direct T Cell Activation by Chimeric Single Chain Fv-Syk Promotes Syk-Cbl Association and Cbl Phosphorylation* (1997) (33)
- Production of Monoclonal Antibodies to Steroid Hormones (1982) (33)
- Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit. (1998) (32)
- Induction if immunological tolerance to the major antigenic determinant of penicillin: a therapeutic approach to penicillin allergy. (1976) (32)
- Affinity chromatography of human fibroblast interferon (IFN-beta 1) by monoclonal antibody columns. (1983) (30)
- Redirected tumor-specific allogeneic T cells for universal treatment of cancer. (2011) (29)
- LFA-1 but not Lyt-2 is associated with killing activity of cytotoxic T lymphocyte hybridomas (1982) (29)
- Catalytic antibodies. Circular dichroism and UV-vis studies of antibody-metalloporphyrin interactions (1992) (29)
- Genetic regulation of delayed-type hypersensitivity responses to poly(LTyr,LGlu)-poly(DLAla)--poly(LLys). II. Evidence for a T-T-cell collaboration in delayed-type hypersensitivity responses and for a T- cell defect at the efferent phase in nonresponder H-2k mice (1980) (27)
- Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach. (1990) (26)
- Relationships between epitopes on IgE recognized by defined monoclonal antibodies and by the FC epsilon receptor on basophils. (1986) (26)
- ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor. (2004) (26)
- pH on-off switching of antibody-hapten binding by site-specific chemical modification of tyrosine. (1994) (26)
- Induction of tolerance to nucleic acid determinants by administration of a complex of nucleoside D-glutamic acid and D-lysine (D-GL). (1975) (26)
- 1,8-Diazabicyclo[5.4.0]undecene Mediated Transesterification of p-Nitrophenyl Phosphonates: A Novel Route to Phosphono Esters (1993) (25)
- Preparation of monoclonal antibodies able to discriminate between testosterone and 5α-dihydrotestosterone (1982) (25)
- CAR T cells: Building on the CD19 paradigm (2021) (25)
- CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor‐antigen complex (1991) (24)
- From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells. (2014) (24)
- Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer (2014) (24)
- Activation of T and B lymphocytes in vitro. VI. Biochemical and physicochemical characterization of the allogeneic effect factor. (1977) (23)
- Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy. (1995) (22)
- Efficient and selective p-nitrophenyl-ester-hydrolyzing antibodies elicited by a p-nitrobenzyl phosphonate hapten. (1997) (20)
- Monoclonal antibodies specific to the alpha-subunit of the mast cell's Fc epsilon R block IgE binding and trigger histamine release. (1987) (20)
- Catalytic antibodies: A critical assessment (1994) (19)
- Anti-IgE monoclonal antibodies directed at the Fcϵ receptor binding site (1988) (19)
- Monoclonal antibodies for affinity purification of IL-6/IFN- beta 2 and for neutralization of HGF activity. (1989) (18)
- Human monoclonal antibody derived from an autoimmune thrombocytopenic purpura patient, recognizing an intermediate filament's determinant common to vimentin and desmin. (1990) (18)
- P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas (2021) (18)
- Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts (2008) (18)
- Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes (1995) (18)
- Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies. (1997) (17)
- The human mast cell receptor binding site maps to the third constant domain of immunoglobulin E. (1992) (17)
- Anti‐schistosome monoclonal antibodies of different isotypes–correlation with cytotoxicity. (1983) (17)
- Interspecies comparison of prostate cancer gene‐expression profiles reveals genes associated with aggressive tumors (2009) (17)
- Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. (2018) (16)
- Solubilization of lymphocyte and thymocyte antigens by a reversible chemical modification (1971) (16)
- Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells. (1999) (15)
- Activation of T and B lymphocytes in vitro. V. Cellular locus, metabolism and genetics of induction, and production of the allogeneic effect factor. (1977) (15)
- Monoclonal Antibodies to the Human Interferon-γ Receptor: Blocking of the Biological Activities of Interferon-γ and Purification of the Receptor (1989) (15)
- RAB-1: a new monoclonal antibody to leukemic hairy cells. (1986) (15)
- Immune regulation of experimental myasthenia. (1980) (15)
- Detection of catalytic monoclonal antibodies. (1992) (14)
- Monoclonal anti‐VH antibodies recognize a common VH determinant expressed on immunoglobulin heavy chains from various species (1983) (14)
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the y or C subunits of the immunoglobulin and T-cell receptors ( single-chain Fv domain / chimeric receptors / Immunotargeting / T cell ) (2004) (14)
- Mixed alkanethiol monolayers on submicrometric gold patterns: a controlled platform for studying cell-ligand interactions. (2012) (14)
- T-Bodies: Chimeric T-Cell Receptors with Antibody-Type Specificity (1995) (13)
- Cell fractionation with affinity ligands conjugated to agarose-polyacrolein microsphere beads. (1983) (13)
- Novel assay procedure for assessing ovarian function in women. (1981) (13)
- Mechanism of inactivation of a catalytic antibody by p-nitrophenyl esters. (1997) (12)
- Mapping of distinct structural domains on microtubule-associated protein 2 by monoclonal antibodies. (1982) (12)
- Characteristics of a poly(LTyr,LGlu)‐poly(DLAla)–poly(LLys)‐specific helper factor derived from a T cell hybridoma (1981) (12)
- Genetic regulation of delayed-type hypersensitivity responses to poly(LTyr,LGu)-poly(DLAla)--poly(LLys). I. Expression of the genetic defect at two phases of the immune process (1980) (12)
- Somatic cell hybridization between bovine leukemia virus-infected lymphocytes and murine plasma cell tumors: cell fusion studies with bovine cells. (1982) (12)
- Characterization and partial purification of antigenic components solubilized by a reversible chemical modification from rat-thymocyte membrane. (1972) (11)
- Esterolytic antibodies as mechanistic and structural models of hydrolases-a quantitative analysis. (2002) (11)
- WISH-PC 2 : A Unique Xenograft Model of Human Prostatic Small Cell Carcinoma 1 (2000) (11)
- Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity (2020) (11)
- Characterization of soman-binding antibodies raised against soman analogs. (1992) (11)
- Serological characterisation of citrus tristeza virus isolates from Israel (1994) (10)
- Variability and repertoire size of T-cell receptor V alpha gene segments. (1985) (10)
- Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach (2020) (10)
- Functional assembly of chimeric T-cell receptor chains. (1992) (9)
- Monoclonal antibodies to the synthetic adjuvant muramyl dipeptide: characterization of the specificity. (1983) (9)
- Study on Adoptive Immunotherapy Using Gene-Modified TCells for Ovarian Cancer (2006) (9)
- Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer (2011) (9)
- A Human Monoclonal Antibody to Insulin (1986) (9)
- Crossreactivity, efficiency and catalytic specificity of an esterase-like antibody. (1998) (8)
- HISTOCOMPATIBILITY GENE PRODUCTS AS MEDIATORS OF LYMPHOCYTE INTERACTIONS (1976) (8)
- Thymus-derived rat lymphocyte receptor for cell surface antigens is a nonserologically defined product of the major histocompatibility gene complex. (1975) (8)
- Fine specificity and idiotypic expression of monoclonal antibodies directed against poly(Tyr,Glu)-poly(DLAla)--poly(Lys) and its ordered analogue (Tyr-Tyr-Glu-Glu)-poly(DLAla)--poly(Lys). (1983) (8)
- Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immunotoxin. (1996) (7)
- Opinion paper on the current status of the regulation of gene therapy in Europe. (2002) (7)
- Anti-leucocyte function-associated antigen-1 antibodies inhibit T-cell activation following low-avidity and adhesion-independent interactions. (1993) (7)
- Identification of a surface antigen, common to murine lung and lewis lung carcinoma, by monoclonal antibody (1984) (7)
- Electrically controlled molecular recognition harnessed to activate a cellular response. (2011) (7)
- T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields (2021) (6)
- Functional cytotoxic T lymphocyte hybridomas. (1981) (6)
- Organ-specific homing of B-cell hybridomas. (1982) (6)
- CHANGES IN TUMOROGENIC AND METASTATIC PATTERN OF THYMOMA CELLS INDUCED BY THEIR HYBRIDIZATION TO NORMAL LYMPHOCYTES (1982) (6)
- Tumor-specific allogeneic cells for cancer therapy (2011) (6)
- Genetic regulation of delayed-type hypersensitivity responses to poly (Tyr,Glu)-poly(DLAla)--poly(Lys): expression of the genetic defect in the induction and manifestation phases in H-2s and H-2f mice. (1982) (5)
- Cytotoxic T cell hybridomas: generation and characterization. (1982) (5)
- T-bodies as antiviral agents. (2001) (5)
- Gene Expression Profiles Predict Sensitivity of Prostate Cancer to Radiotherapy (2013) (4)
- 1,8-Diazabicyclo(5.4.0)undecene-Mediated Transesterification of p- Nitrophenyl Phosphonates: A Novel Route to Phosphono Esters. (1994) (4)
- Monoclonal Antibodies to Human Leukocyte and Fibroblast Interferon (1983) (4)
- Anti‐anti‐IgE idiotypic antibodies mimic IgE in their binding to the Fcϵ receptor (1987) (4)
- Functional relationships of lymphocyte membrane structures probed with cytolysis and/or proliferation-inhibiting H35-27.9 and H35-89.9 monoclonal antibodies. (1982) (4)
- Target discovery for T cell therapy: next steps to advance Immunotherapies (2015) (4)
- Monoclonal antibodies to the human interferon-gamma receptor: blocking of the biological activities of interferon-gamma and purification of the receptor. (1989) (3)
- T cell hybridomas producing antigen-specific factors express heavy-chain variable-region determinants. (1982) (3)
- Adoptive immunotherapy of cancer using effector lymphocytes redirected with antibody specificity (2006) (3)
- Anti-IgE monoclonal antibodies directed at the Fc epsilon receptor binding site. (1988) (3)
- Specificity of heterologous antisera to components solubilized from rat thymocyte membranes (1973) (3)
- CONTROL OF IMMUNOCOMPETENT CELL DIFFERENTIATION AND FUNCTION BY PRODUCTS OF THE MAJOR HISTOCOMPATIBILITY GENE COMPLEX (1976) (3)
- Serological analysis of idiotypic determinants on monoclonal antibodies specific to poly(Tyr,Glu)-poly(DLAla)--poly(Lys) and its ordered analogue (Tyr-Tyr-Glu-Glu)-poly(DLAla)--poly(Lys). (1984) (3)
- Preparation of monoclonal antibodies able to discriminate between testosterone and 5 alpha-dihydrotestosterone. (1982) (3)
- Functional expression in mast cells of chimeric receptors with antibody specificity (2007) (3)
- Adoptive Cell Therapy of Systemic Metastases Using erbB-2-Specific T Cells Redirected with a Chimeric Antibody-Based Receptor (2014) (2)
- Production of hybridomas secreting monoclonal antibodies against components of normal and malignant cells. (1980) (2)
- Mapping of murine IgE epitopes involved in IgE-Fc epsilon receptor interactions. (1989) (2)
- The T‐Body Approach: Towards Cancer Immuno‐Gene Therapy (2003) (2)
- Redirecting immune cells against bone metastases: Immunotherapy of prostate cancer metastases using genetically programmed immune effector cells. (2005) (2)
- THE DIFFERENCES IN STRUCTURE BETWEEN SECRETED AND CELL SURFACE MEMBRANE IMMUNOGLOBULINS (1979) (2)
- Organ specific neoantigens reactive in the leukocyte adherence inhibition assay: affinity purification of human colon carcinoma antigen and its cross-reactive protein using monoclonal antibodies. (1986) (2)
- Isolation of thymocytes by affinity chromatography. (1974) (1)
- From Phosphonates to Catalytic Antibodies. A Novel Route to Phosphonoester Transition State Analogs and Haptens (1993) (1)
- Catalytic Antibodies as Mechanistic and Structural Models of Hydrolytic Enzymes (2008) (1)
- Contents, Vol. 94, 1991 (1991) (1)
- CAR's made it to the pancreas (2012) (1)
- T-Bodies: Antibody-Based Engineered T-Cell Receptors (2014) (1)
- P12.05 Evaluating the compatibility of tumor treating electric fields with key antitumoral immune functions (2019) (1)
- Localization of the FcεRI binding site to the third constant domain of IgE (1991) (1)
- Modifying the specificity of T cells using chimeric Ig/TCR genes (1993) (1)
- Monoclonal Antibodies for Purification and RIA of Natural and Recombinant Human Interferon-α, -β And-γ (1985) (1)
- Differences Amoung Individual CEA Preparations and Carcinomas of Different Origin as Detected by Monoclonal Anti-CEA Antibodies (1984) (1)
- Towards Antibody‐Mediated Metallo‐Porphyrin Chemistry (1991) (1)
- Abstract 621: Evaluating the compatibility of tumor treating electric fields with key anti-tumoral T cell functions (2018) (0)
- Functional T Cell Hybridomas Producing Antigen-Specific Immunoregulatory Factors (2019) (0)
- Suppression of anti-nucleoside response by administration of a complex of nucleoside d-glutamic acid and d-lysine (d-gl). Abstr. (1975) (0)
- Differences among individual CEA preparations detected by monoclonal antibodies (1982) (0)
- CTL-based immunotherapy (PP-109) (2010) (0)
- 596: Is there a Role for Androgen Ablative Therapy for Hormone Refractory Prostate Cancer? (2004) (0)
- A monoclonal antibody against a cytotoxin, the same producing hybridomas and methods for preparing the purified cytotoxin. (1985) (0)
- Suppression of anti-penicillin reaginic antibody responses by penicillin coupled to a "d" amino acid copolymer. Abstr. (1976) (0)
- CAR mediated redirection of Teff and Treg cells for the treatment of cancer and autoinflammation (P4340) (2013) (0)
- REROUTED, GENETICALLY MODIFIED regulatory T cells and their use for suppressing autoimmune inflammatory disease AND (2008) (0)
- GENETICALLY ENGINEERED THERAPEUTIC ANTIBODIES (2001) (0)
- Defect at the Efferent Phase in N o n re sp o n d e r H-2 k Mice (2003) (0)
- Loss of Original Antigenic Specificity in T Cell Hybridomas Transduced with a Chimeric Receptor Containing Single-Chain Fv of an Anti-Collagen Antibody and FcεRI-Signaling γ Subunit (1998) (0)
- Screening process for catalytic non-enzyme-polypeptide and-proteins (1994) (0)
- Localization of the Fc epsilon RI binding site to the third constant domain of IgE. (1991) (0)
- Monoclonal antibodies against carcinoembryonic antigen (CEA) discriminate between CEA produced by gastrointestinal tumors and CEA produced by other tumors. (1990) (0)
- Mono clonal antibodies to human interferon alpha beta and gamma (1983) (0)
- Chimeric receptor genes and correspondingly transformed cells thus (1993) (0)
- The T-body approach combining antibody specificity with T cell activity for adoptive vaccination of cancer (2013) (0)
- Induction of Fc epsilon receptors on normal murine T cells and IgE binding factor(s) by cross-linked IgE or IgE-pulsed adherent cells. (1986) (0)
- Induction of immunological tolerance to the major antigenic determinant of penicillin : A therapeutic approach to penicillin allergy [ benzylpenicilloyl-poly ( DGlu , Lys ) / IgE reaginic antibodies / bone-marrow-derived lymphocytes / human allergies / immunotherapy ] (0)
- Biographical Sketch of Dr. Alec H. Sehon (1991) (0)
- 264. Immune Gene-Therapy of Cancer Using Redirected Naïve or Effector Lymphocytes (2006) (0)
- 1060 Redirecting Effector Lymphocytes for Adoptive Cell Therapy of Pancreatic Adenocarcinoma in Mice (2012) (0)
- Lymphocytes and Antitumor Activity Leads to Enhanced Survival of Transduced T Receptor with Modified Signaling Domains A Herceptin-Based Chimeric Antigen (2009) (0)
- P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas (2021) (0)
- Mono clonal antibodies to the nicotinic acetyl choline receptor (1981) (0)
- Like Lytic Peptide − Systemic Inoculation of a Host Defense Metastases in Human Prostate and Breast Xenografts by Inhibition of Tumor Growth and Elimination of Multiple (2006) (0)
- Abstract 3954: Evaluating the compatibility of tumor treating electric fields with key anti-tumoral immune functions (2019) (0)
- catELISAELISA-based detection of catalytic antibodies and enzymes1 (1996) (0)
- Crystal structure of an abzyme having an esterase activity (1993) (0)
- Detection of small molecules with piezo-electric sensor (2000) (0)
- IMMU-71. EVALUATING THE COMPATIBILITY OF TUMOR TREATING ELECTRIC FIELDS WITH KEY ANTI-TUMORAL T CELL FUNCTIONS (2018) (0)
- Monoclonal Antibodies Progress To the Next Generation (1995) (0)
- Ferritin , a Hodgkin ' s Disease Associated Antigen ( spleen / Fand S-antigens / lymph nodes / fetal liver ) (0)
- Antibodies in the Gene Therapy of Cancer (2002) (0)
- New Strategy for the Redirection of Cytolytic T Lyphocytes to Breast Tumors (2001) (0)
- Anti-Collagen Antibody and Fc Receptor Containing Single-Chain Fv of an Chimeric Cell Hybridomas Transduced with a Loss of Original Antigenic Specificity in T (2017) (0)
- 19th Annual meeting of the Israel Immunological Society : abstracts, May, 1989, Rehovot, Israel (1990) (0)
- MONOCLONAL ANTI-CYTOSKELETON ANTIBODY DERIVED FROM AN ITP PATIENT (1987) (0)
- Tumor immunotherapy using chimeric receptor redirected allogeneic T cells across MHC barriers (131.39) (2010) (0)
- Adoptive Transfer of T-Bodies: Toward an Effective Cancer Immunotherapy (2009) (0)
- Thymus-Derived Rat Lymphocyte Recepto Nonserologically Defined Product of the 1 Histocompatibility Gene Complex (2016) (0)
- 1017. Genetic Predisposition of the Sensitivity of Prostate Cancer to Radiatherapy (2006) (0)
- STRUCTURES OF ESTERASE-LIKE CATALYTIC ANTIBODIES (1999) (0)
- Adoptive cell therapy of cancer and autoimmune diseases employing genetically T cells with redirected antibody specificity (2013) (0)
- The Use of Mouse/Human IgE Chimeras to Map the FcϵR Binding Site of IgE (1995) (0)
- Structural studies of catalytic antibodies with esterase activity (1996) (0)
- Models for catalytic antibodies: a tool for understanding their mechanism of action (1993) (0)
- Hierarchy of T cell lineage decision is regulated by thymic self-reactive signaling (36.45) (2010) (0)
- Immunotherapy of pancreatic adenocarcinoma using adoptive cell transfer of redirected T lymphocytes (48.6) (2011) (0)
- Redirected, genetically modified regulatory T cells and their use in the suppression of autoimmune and inflammatory diseases (2008) (0)
- Thymius-Derived Rat Lymphocyte Receptor for Cell Surface Antigens Is a Nonserologically Defined Product of the Major (0)
- X-Ray structures of two families of hydrolytic antibodies (1998) (0)
- Mono clonal antibodies against tumor lung associated antigen of murine lewis lung carcinoma (1980) (0)
- T cell derived IgE binding factors inhibit IgE-specific rosettes on basophilic leukaemic cells and lymphocytes. (1986) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Zelig Eshhar?
Zelig Eshhar is affiliated with the following schools:
